Equities

Cambium Bio Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CMB:ASX

Cambium Bio Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.57
  • Today's Change0.000 / 0.00%
  • Shares traded500.00
  • 1 Year change+54.05%
  • Beta-0.4386
Data delayed at least 20 minutes, as of Feb 09 2026 00:15 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cambium Bio Limited is an Australia-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The Company’s lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. It contains enriched levels of regenerative factors, protease inhibitors, minerals and vitamins. In addition, the Company's stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It is also developing Sygenus, a preclinical secretome-based biologic for wound healing.

  • Revenue in AUD (TTM)670.05k
  • Net income in AUD-3.84m
  • Incorporated2007
  • Employees--
  • Location
    Cambium Bio Ltd2 Paddington Street, PaddingtonPYMBLE 2021AustraliaAUS
  • Phone+61 29499-8010
  • Fax+61 29499-8020
  • Websitehttps://www.cambium.bio/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Invion Ltd0.00-8.81m7.11m8.00--0.8538-----0.1183-0.11830.000.09720.00-------70.63-29.16-77.64-30.88-------147.34----0.00---100.00---56.50------
Biotron Ltd0.00-318.57k8.11m4.00--7.21-----0.0004-0.00040.000.00040.00-------43.23-86.63-206.95-112.69------------0.00------90.73------
Vectus Biosystems Ltd18.77k-1.78m8.28m--------441.24-0.0334-0.03340.0004-0.00480.0134--0.0266---126.57-79.19-247.24-189.44-----9,468.62-10,165.010.9301-554.06-----75.5873.6123.99------
Percheron Therapeutics Ltd371.10k-14.92m8.70m8.00--0.8696--23.44-0.0149-0.01490.00040.00920.0275--0.2824---110.67-79.28-153.98-96.61-----4,021.00-3,694.96---1,093.500.0026---39.7164.80-25.19---6.74--
Chimeric Therapeutics Ltd3.97m-10.43m8.84m----2.14--2.23-0.0071-0.00710.00290.00090.2154--1.73---56.62-66.67-171.92-112.0278.66---262.83-2,013.07---62.300.7162------16.76------
Invex Therapeutics Ltd461.52k-476.87k9.02m----1.72--19.54-0.0063-0.00630.00610.06980.0797--4.92---8.23-15.04-8.72-15.74-----103.33-419.12----0.00---72.9222.7470.95------
Imagion Biosystems Ltd1.06m-2.20m11.77m--------11.15-0.0177-0.01770.0082-0.01921.45--1,173.13---302.58-76.63---102.36-----208.52-911.24---0.7972-----18.5422.0283.43------
Nexsen Ltd-100.00bn-100.00bn11.78m--------------------------------------------------47.44---605,140.90------
Adalta Ltd695.66k-4.50m12.75m--------18.33-0.0059-0.00590.0009-0.00050.1804--0.4992---116.72-70.41-216.60-126.24-----647.19-207.18---75.411.51---61.02-28.9716.33------
Cambium Bio Ltd670.05k-3.84m13.09m----5.68--19.54-0.3489-0.34890.05960.10040.1498--2.58---85.96-41.30-146.56-75.4470.04---573.73-118.71----0.2082--419.43-16.63-70.42------
BPH Energy Ltd836.64k6.79m14.89m2.00k1.940.3467--17.800.00570.00570.00070.03170.0241--10.59--19.549.0519.929.45----811.09431.04----0.0022---0.834428.3448.9343.33----
Noxopharm Ltd2.83m-4.88m17.24m1.00k--24.99--6.09-0.0167-0.01670.00970.00240.4979--1.06---85.95-49.70-156.33-59.16-----172.63-229.01----0.7823--17.54-19.45-36.50------
Neurotech International Ltd2.58m-10.60m17.50m----4.80--6.78-0.0103-0.01030.00250.00280.3341--12.69---137.17-130.68-142.71-148.274.41---410.57-428.9311.34--0.00---22.6199.30-109.08------
Patrys Ltd828.54k-3.01m18.19m15.00--10.30--21.95-0.0156-0.01560.00430.00330.2808--0.7647---102.13-58.09-143.30-63.36-----363.69-250.93----0.00---40.571.4014.86------
Data as of Feb 09 2026. Currency figures normalised to Cambium Bio Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.